Abstract P5-19-22: A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer
Keyword(s):
Phase I
◽
2019 ◽
Vol 25
(17)
◽
pp. 5212-5220
◽